Precore and core promoter mutations at the time of HBeAg seroclearance in Chinese patients with chronic hepatitis B.

Autor: Yuan HJ; Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong, PR China., Ka-Ho Wong D, Doutreloigne J, Sablon E, Lai CL, Yuen MF
Jazyk: angličtina
Zdroj: The Journal of infection [J Infect] 2007 May; Vol. 54 (5), pp. 497-503. Date of Electronic Publication: 2006 Sep 25.
DOI: 10.1016/j.jinf.2006.08.011
Abstrakt: Objective: To determine the prevalence of precore and core promoter (CP) mutations before, at and after HBeAg seroclearance in Chinese patients.
Methods: Precore and CP mutations were determined in 93 patients with chronic hepatitis B 12-24 months before, at and 12 months after the time of HBeAg seroclearance.
Results: No significant changes were found in the prevalence of precore or CP mutations before, at and after HBeAg seroclearance. Seven patients (7.8%) had HBeAg seroreversion within 1 year of HBeAg seroclearance. There was no significant difference in the prevalence of precore and CP mutations between patients with and without HBeAg seroreversion. 68.3% and 48.7% of patients harbored the same precore and CP genotypes throughout. 32.0% patients with precore mutations and 8.9% patients with CP mutations before HBeAg seroclearance had reversion to wild type within 1 year of HBeAg seroclearance. Patients with genotype C patients had a higher prevalence of CP mutations before HBeAg seroclearance compared with patients with genotype B (82.4% vs. 44%, P=0.001).
Conclusions: Precore and CP mutations existed in a substantial proportion of Chinese patients before HBeAg seroclearance. The replication of precore and, to a lesser extent, CP mutants could be suppressed around the time of HBeAg seroclearance.
Databáze: MEDLINE
Externí odkaz: